MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Intra-Cellular Therapies Inc

Cerrado

SectorSanidad

131.89 -0.02

Resumen

Variación precio

24h

Actual

Mínimo

131.89

Máximo

131.89

Métricas clave

By Trading Economics

Ingresos

9.4M

-17M

Ventas

24M

199M

BPA

-0.16

Margen de beneficios

-8.475

Empleados

860

EBITDA

9.8M

-29M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

-0.79% downside

Dividendos

By Dow Jones

Próximas Ganancias

6 may 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

1.8B

14B

Apertura anterior

131.91

Cierre anterior

131.89

Noticias sobre sentimiento de mercado

By Acuity

51%

49%

320 / 386 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bullish Evidence

Intra-Cellular Therapies Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

13 ene 2025, 12:11 UTC

Adquisiciones, fusiones, absorciones

Johnson & Johnson to Acquire Intra-Cellular in $14.6 Billion Deal

13 ene 2025, 11:40 UTC

Adquisiciones, fusiones, absorciones

Johnson & Johnson in Talks to Acquire Intra-Cellular Therapies, Says Bloomberg

14 mar 2025, 09:30 UTC

Principales Noticias

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

22 ene 2025, 14:09 UTC

Principales Noticias
Ganancias

Johnson & Johnson Beats Earnings Estimates and Forecasts 2025 Growth -- Barrons.com

22 ene 2025, 11:22 UTC

Principales Noticias
Ganancias

Johnson & Johnson Beats Earnings Estimates and Forecasts 2025 Growth -- Barrons.com

13 ene 2025, 21:20 UTC

Adquisiciones, fusiones, absorciones

J&J Announces A Splashy $14.6 Billion Deal, While Lilly Tacks On A Cancer Drug -- IBD

13 ene 2025, 20:12 UTC

Principales Noticias
Adquisiciones, fusiones, absorciones

Johnson & Johnson to Acquire Intra-Cellular in $15 Billion Deal -- Update

13 ene 2025, 16:18 UTC

Principales Noticias
Adquisiciones, fusiones, absorciones

Johnson & Johnson to Acquire Intra-Cellular in $15 Billion Deal -- WSJ

13 ene 2025, 15:57 UTC

Adquisiciones, fusiones, absorciones

Johnson & Johnson Bets Big on Mental Health Drugs With $14.6 Billion Intra-Cellular Deal -- Barrons.com

13 ene 2025, 14:10 UTC

Adquisiciones, fusiones, absorciones

Johnson & Johnson Buys Intra-Cellular Therapeutics In A Whopping $14.6 Billion Deal -- IBD

13 ene 2025, 12:25 UTC

Adquisiciones, fusiones, absorciones

Johnson & Johnson in $14.6 Billion Deal to Buy Biotech Intra-Cellular -- Barrons.com

13 ene 2025, 11:57 UTC

Adquisiciones, fusiones, absorciones

Johnson & Johnson Confirms $14.6 Billion Deal to Buy Biotech Intra-Cellular -- Barrons.com

13 ene 2025, 11:56 UTC

Principales Noticias
Adquisiciones, fusiones, absorciones

Johnson & Johnson to Acquire Intra-Cellular in $14.6B Deal

13 ene 2025, 11:45 UTC

Adquisiciones, fusiones, absorciones

Johnson & Johnson: Intra-Cellular's Clinical-Stage Pipeline Has Best-In-Disease Potential in Generalized Anxiety Disorder, Alzheimer's Treatments >JNJ

13 ene 2025, 11:43 UTC

Adquisiciones, fusiones, absorciones

Johnson & Johnson: Caplyta Solidifies Sales Above Analyst Expectations Through Remainder of Decade>JNJ

13 ene 2025, 11:43 UTC

Adquisiciones, fusiones, absorciones

Johnson & Johnson: Caplyta Has Potential of Over $5 Billion in Peak Yr Sales >JNJ

13 ene 2025, 11:42 UTC

Adquisiciones, fusiones, absorciones

Johnson & Johnson Purchases Intra-Cellular for $132/Shr in Cash, or About $14.6B >JNJ

13 ene 2025, 11:41 UTC

Adquisiciones, fusiones, absorciones

Johnson & Johnson: SNDA Submitted to FDA for Caplyta as Adjunctive Treatment for Major Depressive Disorder >JNJ

13 ene 2025, 11:40 UTC

Adquisiciones, fusiones, absorciones

Johnson & Johnson: Acquisition Includes CaplytaTreatment for Bipolar I and II Depression, Schizophrenia >JNJ

13 ene 2025, 11:34 UTC

Adquisiciones, fusiones, absorciones

Johnson & Johnson: Deal Adds Intra-Cellular's Caplyta Depression Drug >JNJ ITCI

13 ene 2025, 11:32 UTC

Adquisiciones, fusiones, absorciones

Johnson & Johnson: To Maintain Strong Balance Sheet, Continue to Support Capital-Allocation Priorities >JNJ

13 ene 2025, 11:32 UTC

Adquisiciones, fusiones, absorciones

Johnson & Johnson To Fund Transaction With Cash on Hand, Debt >JNJ ITCI

13 ene 2025, 11:31 UTC

Adquisiciones, fusiones, absorciones

Johnson & Johnson to Buy Intra-Cellular Therapies for About $14.6 Billion >JNJ ITCI

13 ene 2025, 11:31 UTC

Adquisiciones, fusiones, absorciones

Johnson & Johnson to Buy Intra-Cellular Therapies for $132/Share in Cash >JNJ ITCI

13 ene 2025, 11:30 UTC

Adquisiciones, fusiones, absorciones

Johnson & Johnson Strengthens Neuroscience Leadership With Acquisition Of Intra-Cellular Therapies, Inc. >JNJ ITCI

13 ene 2025, 10:55 UTC

Adquisiciones, fusiones, absorciones

This Stock Is Soaring Amid Johnson & Johnson Takeover Report -- Barrons.com

13 ene 2025, 10:41 UTC

Adquisiciones, fusiones, absorciones

This Stock Is Soaring Amid J&J Takeover Report. What to Know. -- Barrons.com

Comparación entre iguales

Cambio de precio

Intra-Cellular Therapies Inc previsión

Precio Objetivo

By TipRanks

-0.79% descenso

Estimación a 12 Meses

Media 130.83 USD  -0.79%

Máximo 132 USD

Mínimo 118 USD

De acuerdo con 13 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Intra-Cellular Therapies Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

13 ratings

4

Comprar

9

Mantener

0

Vender

Puntuación técnica

By Trading Central

131.45 / 131.87Soporte y Resistencia

Corto Plazo

Weak Bullish Evidence

Medio plazo

No Evidence

Largo Plazo

No Evidence

Sentimiento

By Acuity

320 / 386 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura bajista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Intra-Cellular Therapies Inc

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.